Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC

NCT03526887 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

73

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: Pembrolizumab
DRUG: Pembrolizumab

Sponsor

Spanish Lung Cancer Group